Owkin CEO Thomas Clozel (L) and CSO Gilles Wainrib
June 8, 2022 11:13 AM EDTUpdated 11:54 AM
Deals
AI

Fol­low­ing tie-up with Sanofi, transat­lantic AI firm se­cures lat­est Big Phar­ma deal in nine-fig­ure Bris­tol My­ers pact

Paul Schloesser

Associate Editor

More than six months af­ter se­cur­ing a nine-fig­ure deal with Sanofi for tar­get dis­cov­ery, a French AI re­search group has land­ed its next Big Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times